GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Cash Received from Insurance Activities

SCYNEXIS (LTS:0L49) Cash Received from Insurance Activities


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Cash Received from Insurance Activities?

Cash Received from Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.


SCYNEXIS (LTS:0L49) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Cash Received from Insurance Activities
Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.